Patents by Inventor Pingping Hou

Pingping Hou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR USE IN KRAS-TARGETED THERAPIES FOR THE TREATMENT OF CANCER
    Publication number: 20250339520
    Abstract: Methods and compositions for the treatment of cancer are disclosed herein. More specifically, disclosed herein are methods and compositions for the treatment of KRASi resistant cancers using NFAT5 inhibitors.
    Type: Application
    Filed: May 1, 2025
    Publication date: November 6, 2025
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Pingping Hou, Daiyong Deng
  • Compositions and methods for reprograming non-pluripotent cells into pluripotent stem cells
    Patent number: 9982237
    Abstract: The invention provides a composition and a method for inducing pluripotency in non-pluripotent eukaryotic cells. The composition comprises chemical inducers of pluripotency (CIPs) including glycogen synthase kinase (GSK) inhibitors, TGFp receptor inhibitors, cyclic AMP agonists, S-adenosylhomocysteine hydrolase (SAH) inhibitors, and optionally an agent that promotes histone acetylation. The method comprises contacting a cell with the CIPs for a sufficient period of time to reprogram the cell into a pluripotent stem cell.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: May 29, 2018
    Assignee: Hong Guan, Ltd.
    Inventors: Hongkui Deng, Yang Zhao, Pingping Hou, Yanqin Li, Xu Zhang, Chun Liu, Jingyang Guan, Honggang Li
  • COMPOSITIONS AND METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS
    Publication number: 20160145581
    Abstract: The invention provides a composition and a method for inducing pluripotency in non-pluripotent eukaryotic cells. The composition comprises chemical inducers of pluripotency (CIPs) including glycogen synthase kinase (GSK) inhibitors, TGFp receptor inhibitors, cyclic AMP agonists, S-adenosylhomocysteine hydrolase (SAH) inhibitors, and optionally an agent that promotes histone acetylation. The method comprises contacting a cell with the CIPs for a sufficient period of time to reprogram the cell into a pluripotent stem cell.
    Type: Application
    Filed: July 10, 2014
    Publication date: May 26, 2016
    Inventors: Hongkui Deng, Yang Zhao, Pingping Hou, Yanqin Li, Xu Zhang, Chun Liu, Jingyang Guan, Honggang Li